| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9855f853f24337072ce02f44383942c9 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/H01J49-0036
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/H01J49-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57423
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6848
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-179
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-49 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B40-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B40-10 |
| filingDate |
2014-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_928f9d858dc414885fff40e10445171a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_acb081db25f2b1771a4006eef12de0b5 |
| publicationDate |
2015-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2015178946-A1 |
| titleOfInvention |
Treatment selection for lung cancer patients using mass spectrum of blood-based sample |
| abstract |
A test for predicting whether a non-small-cell lung cancer patient is more likely to benefit from an EGFR-I as compared to chemotherapy uses a computer-implemented classifier operating on a mass spectrum of a blood-based sample obtained from the patient. The classifier makes use of a training set which includes mass spectral data from blood-based samples of other cancer patients who are members of a class of patients predicted to have overall survival benefit on EGFRI-Is, e.g., those patients testing VS Good under the test described in US patent 7,736,905. This class-labeled group is further subdivided into two subsets, i.e., those patients which exhibited early (class label "early") and late (class label "late") progression of disease after administration of the EGFR-I in treatment of cancer. |
| priorityDate |
2014-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |